Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can't wait to see the next Quarterly and Annual reports...
Looks just like JP has been saying...someone has millions of shares to dump, and the only logical assumption is that they are the shares that the company gave themselves to dump in order to pay their own saleries and pension plans...wonder what kind of severance GC has built in when he gets demoted from CEO of daddy's company?
New fluff PR...
Any guess what the PPS will do?
"Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns "
Looking at GC's latest tweet, you may be right!
Hopefully his enthusiasm about ESS for next week will translate into a huge grant announcement?
Who knows...maybe the stars, moons, and the sun will align, and AMBS will start making progress towards commercialization and NASDAQ uplisting?
Long AMBS
Here I thought I was doing well averaging down this morning at $1.25
Looked like a great decision about two hours again...well, looks like I get a chance to average down some more.
Hopefully the selling pressure will cease and the momentum will start picking up again. Elto phase 2B was already underway, so maybe an update on that soon? Maybe an update to one of the orphans? Or announcement of a huge grant of money???
Come on AMBS!!!
Show me the money!
Conference is not put up by AMBS, but they have a briefing spot.
It's sponsored by OTC Markets Group, and AMBS Spot will be on October 1st at 11:30 EDT.
Wouldn't expect any ground breaking news...
Looks like it's just a promotion for the OTCQX Life Sciences Companies.
Looks like just an awareness campaign?
I sure hope the news comes out fast and furious! If the next release is GC buying another asset that will require millions in R&D, or if the plans are to sell another 10M shares, I look for the PPS to drop to about $1.50
Let's hope this is not the case, and the next release will be the NASDAQ uplist!
Otherwise...it could get ugly real fast!
In My Own Personal Opinion!
Long AMBS!
I wouldn't agree that the assets acquired are useless...some are very promising, and may have a huge impact in the medical world. I would however say that he acquired assets that require a fortune in R&D before any potential may be realized. Money that GC just assumed would be handed to him once he owned all the proprietary rights to said assets.
Huge potential....just didn't count on paying for all the research prior to purchasing.
I'm keeping my fingers crossed for Eltoprazine and ESS to produce some form of funding before the end of the year. Either a huge grant...or a JV infusion!
Long AMBS!
In My Own Personal Opinion!
I agree that more funding is necessary, or the company will have to start selling the assets they worked so hard to acquire...but what ever happened to non-dilutive financing?
We had been promised financing grants for years, and even teased with JV deals that couldn't be disclosed due to terms of the agreement. What happened to those supposed deals?
Why not increase the outstanding shares a percentage, instead of motes than doubling them?
I personally have watched my investment decrease by about 70%, and that is stl after averaging down on my pps. I really don't want my portfolio cut in half again by a stock split, or major issuance of new shares.
Better financing needs to happen!
I know their trying to run a world class buisness....but at some point, GC needs to work on increasing his bank account by selling product, and quit borrowing to buy more undeveloped products.
In My Own Personal Opinion Of Course!
Long AMBS!
As much as I am pro AMBS, I have to be concerned about the pps as well. As GC and friends want to triple the outstanding share count, it will go towards the current market cap. So at our current $3.00 pps, we will almost instantly be dropped closer to$1.00. Honestly with the looming vote, it scares the crap out of me. I have a ton of money wrapped up in AMBS, and had anticipated the shares to steadily climb after the reverse split. I would have thought GC would have been releasing news monthly...if not weekly after all the hype of up listing from a position of strength. I'm hoping it's just a stall tactic until we actually do get on NASDAQ...maybe then the news machine will start printing about all the positives in the company....instead of possibilities. A position of strength to me means 1000% gains...not 80% losses that I've been witnessing!
Although still Long AMBS...
Very hesitant until the proxy vote is completed! I know they need more shares to sell, but we have also been promised non-dilutive financing for the past three years! Have we received any? Other than this most recent ARMY grant for ESS? Still don't even know the amount for it either?
May be time to hold some of the other products off until one starts to produce income...so far, each product has done nothing but cost more money! What ever happened to RP? It received orphan designation way before ESS...shouldn't it be in phase 2 or 3 by now?
I hate seeing this company go down in value with so much promise in the pipeline...
It is way undervalued...but I too believe it is due to poor management from GC. Maybe he and his dad should forgo their salaries until a product produces income?
Instead of larger salaries and bonuses for up listing!
In My Own Personal Opinion Of Course!
Long AMBS!
Everyone is upset because..
We have been promised non-dilutive financing for the past three years...
Shareholders were promised to be "taken care of"...
Lympro was to be the "Gold Standard"...
What did we get but a downward spiral since last August...
No updates on RP...
A reverse split from a position of "strength"???
A promise for further dilution by increasing authorized shares...that we all know will become issued and sold for further dilution.
Point is, that there is plenty to be upset about. Management has not been totally honest or upfront with shareholders that got the company this far...some of us have been in AMBS for several years, and are not happy with the acquisitions of assets that require a ton of R&D funds to even investigate whether or not further research is necessary. AMBS cannot and should not continue to finance everything in house...a partner is necessary to avoid some of the dilution. GC said discussions were in the works with a partner more than a year ago! The dilution and decrease in PPS needs to stop! Before much longer, even a turnicate won't help...a limb will have to be removed!
I'm still long, and hoping for the best...but very frustrated as well!
In My Own Personal Opinion Of Course!
Long AMBS!
Yes....
Even better, maybe we can get back to the .10 level before the huge sell off!
Block him....his posts are not illegal. Just click on his name and then click block. Not hard to do
If it does...I'll pick up another $5k
Standing by for the dip....
When is it going to happen exactly?
Before or after the Diagnostics Spinoff?
Before or after the Uplist?
Before or after the close of ESS?
Before or after the start of the Eltoprazine 2b
Your right Sal...nothing to do with news. It just allows time for all brokers and holders of AMBS TO CONVERT THEIR SHARES at the 1/150 rate. That is why the 20 day restriction. I'm pointing out that after the D is dropped, shares will be a little easier to trade on the open market...hence a great reason to drop the news and the hush orders about all the deals in place. Is it going to happen...I don't honestly know?
But, it needs to happen soon to get the pps back up
Day 9 of the 20 day wait...
I really hope GC has four Aces up his sleeve!
July 7th should be the end of the 20 day hold, and then the D will be dropped from AMBSD!
Then, I believe the announcements will be made!
Hopefully we will be back above $10 by the end of July, and looking at equity, instead of this loss he has given us so far...
Best of luck everyone!
In My Own Personal Opinion Of Course!
I'm pretty sure I said something similar in an earlier post...
Someone respectfully disagreed with my assessment though?
This is why the D is in place for the 20 trading day period. All the brokers need to get their share counts adjusted, and all stock owners receive their 1\150 split.
Once that is done....I expect the PR's to start flowing.
Big things are going to happen....as soon as we are stable again.
I tend to believe it's going to be reasonably quiet around here for the next 19 days. Now once the D gets dropped, and we are back to AMBS, I think GC will start dropping the PR's and I expect some traction towards the AMDX spinoff. Mostly because we need a lot more funds to finish the uplist. AMDX, could just be that proverbial ticket to the big show...which I'm guessing will happen around the time of the AAIC.
In My Own Personal Opinion Of Course!
Let's hope the reverse split is tomorrow...then after the 20 day cool off, I'm sure there will be lots of new developments to come out...presumably the NDA regarding AMDX. Not to mention closing the deal on ESS and Georgetown...it will all start lining up soon.
Let's Get-R-Done!
In My Own Personal Opinion Of Course
Between his and his daddy's salary increase...it's over $200k per year....no matter what happens to the company. He has incentive to get us to NASDAQ, with or without strength, his rais only states listing on NASDAQ.
Not aware of any announcements regarding numbers, other than what was approved by the FDA for the Phase 2B. Eltoprazine has already been tested in more than 800 persons, so the FDA knows it is safe in humans. This trial is specifically focused on its effectiveness of treating LID.
$AMBS$ time to get moved up to the big boards!
Aside from some minor day trading, it looks like the majority of shareholders are holding to what they have!
No real buying pressure, no real selling pressure since the announcement of restructuring. If the intent was to get a pps spike before the r/s, it doesn't appear to be working. Looks like everyone just wants to get the r/s behind us so the next phase for the company can begin. Maybe once they start the actual testing, instead of just enrollment? Any way about it...it's time to make the r/s happen, so the major announcements can be released to draw in larger investors with the deep pockets!
GLTA
In My Own Personal Opinion Of Course!
Looks like someone grabbed another 600,000 shares to me!
Pretty smart move if you ask me! These prices won't be here for much longer!
The support at .05 has been unbelievable! It's only up from here!
GLTA
In My Own Personal Opinion Of Course!
You have got to believe that many different catalysts could cause an increase in interest from bigger investment companies. Eltoprazine phase 2B will start this month...or the announcement will be strategically released a day or two before the R/S. I am guessing the Lonza deal will close as well as the Georgetown deal as soon as we make it to Nasdaq. GC does not want to see this company fail, he has as much an interest in its success as anyone. Then with the spinoff of AMDX, if it's not bought outright, it will probably make it to Nasdaq as well. Either way, a huge bonus to shareholders!
This company is going places...with or without believers!
Jump on now, or watch it speed away!
I have my shares!
GLTA. In My Own Personal Opinion Of Course!
$AMBS$. June 2nd Ld Micro Conference
JUNE 2
TIME
10:30 Amarantus Bioscience | AMBS
Who is buying today?
I've got my order in for another 100k!
I have to agree with Alapis...price should be rising very soon!
Look for many announcements as soon as the split has finalized!
In My Own Personal Opinion Of Course!
FINRA Approval could be any day now...could be next week...could be next month?
As a result of the stock split, every 150 shares of issued and outstanding common stock will be converted into 1 share of common stock. Upon FINRA approval the Company's common stock will temporarily trade on the OTCQB under the symbol "AMBSD," for a period of 20 trading days after which time the symbol will revert back to AMBS. The temporary "D" at the end of the Company's stock symbol signifies that the reverse stock split has occurred. Following the reverse split, there will be approximately 7 million common shares outstanding.
$AMBS$. Look for more major announcements right after the r/s!
[quote"The core fundamentals of Amarantus have never been stronger, with the upcoming initiation of our Phase 2b clinical study of our lead product candidate, eltoprazine, in Parkinson's disease levodopa-induced dyskinesia and the pending strategic transaction in our diagnostics division. In addition, we believe the potential addition of the clinical-stage orphan candidate ESS, as part of the potential acquisition of Cutanogen Corporation from Lonza, will complement our orphan preclinical MANF programs, while adding a second clinical-stage therapeutic program to bolster our pipeline.
][/quote]
Does anyone actually believe that the deal with Lonza won't go through? With all the money that AMBS has invested so far, I can only speculate that it is actually payments to complete the deal, and not necessarily payments to "keep the option open". Seems to me that Lonza continues to get the accolades of bringing ESS to fruition and keeping employees employed...while AMBS is waiting for the phase 2 to be completed along with the R/S so hey can make the announcement that the deal is completed!
Why else would they get involved in settling lawsuits that they were not involved in?
In My Own Personal Opinion Of Course!
$AMBS$ ODD process by FDA
What is the review process like once application is received in OOPD? How is a designation application reviewed in OOPD? Please describe the review process for a designation application.
Following receipt of the Orphan designation application, the OOPD review process is as follows: The application is assigned a designation application number and logged into OOPD database and an acknowledgement letter is sent to the sponsor. The assigned OOPD reviewer completes the review of theapplication by preparing a review. The review is forwarded to the OOPD Team Leader for a second level review and concurrence. The review is forwarded for a 3rd level review by the OOPD Office Director. Following the OOPD Director’s concurrence, a designation letter, a letter requesting additional information, or a denial letter is prepared for the Director’s signature and the letter is issued to the sponsor.
I'm guessing we are just not quite there yet...it is a process...not a rule.
Are you referring to the Orphan Drug Designation that was received for RP in both Europe and the US?
SAN FRANCISCO and GENEVA, April 29, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug status for MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of retinitis pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness. The Company previously announced in December of 2014 that it also received orphan drug designation for MANF for the treatment of RP from the U.S. Food and Drug Administration (FDA).
"We are extremely pleased to have received European orphan drug status for our promising investigational product, MANF in RP," said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. "This EU orphan designation, combined with our recent U.S. orphan designation, positions MANF for an accelerated global regulatory product development pathway to address the significant unmet need in this important ophthalmologic indication."
Orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan drug designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure.
David A. Lowe, Ph.D., member of the Amarantus Board Directors, commented, "We believe MANF has potential as a promising potential treatment in multiple orphan ophthalmologic disorders. We intend to continue pursuing the orphan regulatory pathway for MANF as we move this program forward."
About Retinitis Pigmentosa
Retinitis pigmentosa (RP) refers to a group of inherited diseases causing retinal degeneration often leading to blindness. The retina lines the inside back wall of the eye and is responsible for capturing images from the visual field. People with RP experience a gradual decline in their vision because photoreceptor cells (rods and cones) die. Symptoms include a progressive degeneration of peripheral and night vision, as well as a reduction in color perception and central vision. Night blindness is one of the earliest and most frequent symptoms of RP.
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40.
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property around MANF, and is initially focusing on the development of MANF-based protein therapeutics.
MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently pursued. Further applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation.
- See more at: http://globenewswire.com/news-release/2015/04/29/729850/10131354/en/Amarantus-Granted-European-Union-Orphan-Drug-Designation-for-MANF-for-the-Treatment-of-Retinitis-Pigmentosa.html#sthash.w7FQh9py.dpuf
$AMBS$ PD-LID Phase 2b any day now...
But definitely within the next month!
- Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch -
- Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 -
SAN FRANCISCO and GENEVA, May 21, 2015 (GLOBE NEWSWIRE) Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has entered into a clinical trial agreement with Chiltern International (Chiltern), a leading global contract research organization (CRO), to manage the clinical research and monitoring program services for the Phase 2b study of eltoprazine in Parkinson's disease levodopa-induced dyskinesia (PD-LID).
The Company also announced that it has completed its clinical investigator meetings in both the United States and European Union and is on track to commence enrollment and dosing for the 60-patient international, multi-center PD-LID study in the second quarter of 2015.
"We selected Chiltern as our CRO partner for PD-LID Phase 2b development because of their proven excellence in quality and reliability in drug development along with their exceptional expertise in the managing the comprehensive and extensive international clinical study regulatory requirements," said Gerald E. Commissiong, President & CEO of Amarantus. "Now that our investigator meetings have been completed in both the U.S. and the EU, we are ready to commence the eltoprazine dose response, efficacy and safety trial this quarter. The expansion of our team, via our collaboration with Chiltern, will allow us to advance the PD-LID program as efficiently and quickly as possible. The next step is to initiate our first clinical site and begin screening patients for enrollment in the study."
Chiltern will manage all clinical activities related to the Phase 2b eltoprazine study including clinical trial site approval and authorization, investigator and staff training, patient recruitment, timeline and budget monitoring, centralized program tracking systems, regulatory controls and responsibilities, data monitoring committee organization and administration, and trial data quality control and final data lock.
Dr. Jim Esinhart, CEO of Chiltern, added, "Our mission is to provide premier CRO services to innovative and forward-thinking biopharmaceutical companies. As such, we are pleased to partner with Amarantus and manage the initiation of their Phase 2b study with eltoprazine. We recognize that PD-LID can be severely disabling and impact quality of life for Parkinson's patients and utilizing our award-winning trial management program and over 30 years of industry expertise, we look forward to advancing eltoprazine to its next level of clinical development and one-step closer to fulfilling its therapeutic potential for patients with PD."
The Phase 2b eltoprazine trial is a double-blind, placebo-controlled, four-way crossover, dose range finding, clinical study designed to evaluate dose response effect of repeated eltoprazine dosing on safety, tolerability and dyskinesia severity using state-of-the-art rating scales, diaries and motion sensors. Pharmacokinetics and pharmacodynamics will also be evaluated.
About Chiltern International
Chiltern is a leading global CRO that listens to client needs in order to customize solutions for the Biopharma industry. With 33 years in service, Chiltern delivers from three specialized business units: Chiltern Biopharma, with deep therapeutic expertise for respiratory, anti-infectives / vaccines, ophthalmology, dermatology and other specialty areas; Chiltern Oncology, led by physicians, scientists and clinicians to uniquely manage all phases of hematologic and oncologic clinical drug development; and Chiltern Source, a world leader in tailored relationships for FSP, resourcing and staffing solutions. Chiltern's 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are "Designed Around You". Further information is available at: http://www.chiltern.com.
About Eltoprazine
Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID) and adult attention deficit hyperactivity disorder (ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile. Eltoprazine was originally developed by Solvay Pharmaceuticals for the treatment of aggression. Upon Solvay's merger with Abbott Pharmaceuticals, the eltoprazine program was out-licensed to PsychoGenics. PsychoGenics licensed eltoprazine to Amarantus following successful proof-of-concept trials in PD-LID and adult ADHD.
About Parkinson's Disease and Levodopa-Induced Dyskinesia (PD-LID)
Parkinson's disease is a chronic, progressive neurodegenerative disorder that causes motor symptoms such as tremors, rigidity and slowed movements as well as non-motor symptoms including cognitive impairment, mood disorders and autonomic dysfunction. The Parkinson's Disease Foundation estimates that there are approximately one million people living with Parkinson's disease in the United States and seven to 10 million PD patients worldwide. The most commonly prescribed treatments for Parkinson's disease are levodopa-based therapies. In the body, levodopa is converted to dopamine to replace the dopamine loss caused by the disease. As dopamine neurons in the brain are lost the therapeutic efficacy of levodopa attenuates, and increased use is associated with a side effect of dyskinesias. These are involuntary, uncontrollable and often exaggerated and jerky movements. They are distinct from the static, rhythmic tremor as a symptom of Parkinson's disease. Levodopa-induced dyskinesia can be severely disabling, rendering patients unable to perform routine daily tasks.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard?) that led to MANF's discovery.
For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Source: Amarantus BioScience Holdings, Inc.
$AMBS$. Big pay raises coming soon!
Looks like GC makes an additional $113k and Daddy gets an additional $91k per year!
Must be nice to get that kind of pay raise!
Guess there is an incentive to keep it there on the NSDQ!
There has been talk of spinning the Diagnostics Division off for years, and for rewarding current shareholders with a one for one share match. So for every one of the AMBS shares you own, you would get a AMDX share as well. If the valuation stays the same...you have already doubled your money. If it goes up, your net profits increase significantly!
Hey...buy what you can...no one really knows what to expect.
Some investors probably have already pledged millions if GC would uplist...most likely why he added that clause to his and his fathers contracts!
Could be really big money standing by...just waiting for the ink to dry....we shall find out soon enough!
Could truely be a game changer!
Best of luck!
In My Own Personal Opinion Of Course!
$AMBS$ UPLISTING ANYONE???
I wonder if one of the announcements coming at the conferences will be up listing to a NASDAQ exchange???
Wouldn't surprise me.
$AMBS$ Eltoprazine Study???
SO, I wonder just how soon this Phase 2b will be announced...
I wouldn't be surprised if it is not announced at one of the upcoming investor conferences...
Just a thought!
Loving all this volume and accumulation...someone else believes!
$AMBS$ back to the .10 - .15 range!!!
It's going to be so nice to see this continue to run over the next two months.
With all the new developments, conferences, talk of spin off, Eltoprazine phase 2b, and in man studies right around the quarter, this will be back to where it belongs...and quite possibly over .25 when it's all said and done. Should be jumping very soon...I'm sure there are still shorts that need to cover as well as the micro caps getting back in when it hits a dime!!!
AMBS...Money in the Bank!
In My Own Personal Opinion Of Course!
$AMBS$. Loving that end of day accumulation!
Are the shorts finally figuring that it will not be going to go back below .05 after three days in the green!
Sure can't wait for the kick off of the conferences to see what new information will be published!
Go AMBS!!!
$AMBS$ Time for the squeeze to begin!!!
$AMBS$. Here we go...
And the news just keeps coming in!